利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.025 秒)

    MULTIPARTICULATE FORMULATION HAVING TRAMADOL IN IMMEDIATE AND CONTROLLED RELEASE FORM
    4.
    发明申请
    MULTIPARTICULATE FORMULATION HAVING TRAMADOL IN IMMEDIATE AND CONTROLLED RELEASE FORM 审中-公开
    立即释放TRAMADOL的多制剂配方及控制释放形式

    公开(公告)号：US20100047343A1

    公开(公告)日：2010-02-25

    申请号：US12608686

    申请日：2009-10-29

    申请人： John L. Haslam ,  Roger A. Rajewski

    发明人： John L. Haslam ,  Roger A. Rajewski

    IPC分类号： A61K9/58 ,  A61K31/135 ,  A61K9/16

    CPC分类号： A61K9/5084

    摘要： A multi-particulate pharmaceutical composition of rapid release particles and controlled release particles comprising tramadol or a salt thereof is provided. The composition provides a rapid and controlled release of tramadol or a salt thereof in a substantially pH independent manner after oral administration to a subject. The composition can be included in a capsule, caplet, sachet, or other solid dosage form adapted to retain and then release solid pharmaceutical compositions.

    摘要翻译： 提供了包含曲马多或其盐的快速释放颗粒和控制释放颗粒的多颗粒药物组合物。 组合物在口服给予受试者后，以基本上不依赖于pH的方式提供曲马多或其盐的快速和控制释放。 组合物可以包含在适于保持固体药物组合物并随后释放的胶囊，囊袋，小袋或其它固体剂型中。

    Method for precipitation of small medicament particles into use containers
    6.
    发明授权
    Method for precipitation of small medicament particles into use containers 有权
    将小药物颗粒沉淀到使用容器中的方法

    公开(公告)号：US07744923B2

    公开(公告)日：2010-06-29

    申请号：US11870554

    申请日：2007-10-11

    申请人： Roger A. Rajewski ,  Bala Subramaniam ,  Fenghui Niu

    发明人： Roger A. Rajewski ,  Bala Subramaniam ,  Fenghui Niu

    IPC分类号： A61K9/14

    CPC分类号： A61K9/1688 ,  B01J2/02 ,  B01J2/04 ,  B01J2/18

    摘要： Commercially feasible methods for lyophobic precipitation of liquid-dispersed or dissolved material (e.g., medicaments) are provided wherein a plurality of individual, open containers (22) each containing a quantity (84) of a solution or dispersion are treated within a common pressurizable chamber (12). In this process, desired near-supercritical or supercritical temperature and pressure conditions are established for a selected antisolvent gas such as carbon dioxide, and an ultrasonic device (14) is actuated to generate high energy ultrasonic waves in the chamber (12). This leads to intense mixing of the antisolvent with the liquid solution or dispersion within the containers (22), with consequent solvent removal and material precipitation.

    摘要翻译： 提供了用于液体分散或溶解的材料（例如药物）的疏液沉淀的商业上可行的方法，其中每个含有（84）溶液或分散体的多个单独的开放容器（22）在共同的可加压室 （12）。 在这个过程中，为所选择的反溶剂气体例如二氧化碳建立了所需的近临界或超临界温度和压力条件，并且致动超声波装置（14）以在腔室（12）中产生高能超声波。 这导致反溶剂与容器（22）内的液体溶液或分散体的强烈混合，随后进行溶剂去除和材料沉淀。

    PRODRUGS OF (3,5-BIS(4-FLUOROPHENYL)TETRAHYDRO-1H-OXAZOLO[3,4-C]OXAZOL-7A-YL)METHANOL AND DERIVATIVES THEREOF
    7.
    发明申请
    PRODRUGS OF (3,5-BIS(4-FLUOROPHENYL)TETRAHYDRO-1H-OXAZOLO[3,4-C]OXAZOL-7A-YL)METHANOL AND DERIVATIVES THEREOF 失效
    （3,5-二（4-氟代戊基）四氢-1H-咪唑并[3,4-C]氧杂七环-Y-YL）的甲醇及其衍生物

    公开(公告)号：US20100056592A1

    公开(公告)日：2010-03-04

    申请号：US12538619

    申请日：2009-08-10

    申请人： Roger A. Rajewski ,  Mehmet Tanol ,  Ingrid Gunda Georg ,  Michelle P. McIntosh

    发明人： Roger A. Rajewski ,  Mehmet Tanol ,  Ingrid Gunda Georg ,  Michelle P. McIntosh

    IPC分类号： A61K31/4188 ,  C07D235/00 ,  A61P35/00

    CPC分类号： C07D498/04

    摘要： A prodrug that has a prodrug moiety that degrades into a compound having the general Formula I with R3 being an alcoholic moiety can be useful in therapies for neurodegenerative diseases as well as cancer. Accordingly, the prodrug compounds can have a structure of Formula I, analogs thereof, derivatives thereof, or salts thereof, wherein: A and B are sulfur or oxygen; R1 and R2, in para, meta, or ortho position, are independently halogen, alkyl, alkoxy, haloalkyl, where R1 and R2 independently are straight chain, branched, substituted or unsubstituted; and R3 is a prodrug moiety. As examples, the prodrug can have a structure of any of Formulas I-V, which as shown in the specification.

    摘要翻译： 具有降解成具有通式I的化合物的前药部分的前体药物，其中R3是醇部分可用于神经变性疾病以及癌症的治疗。 因此，前药化合物可以具有式I的结构，其类似物，其衍生物或其盐，其中：A和B是硫或氧; R 1和R 2在对位，间位或邻位独立地是卤素，烷基，烷氧基，卤代烷基，其中R 1和R 2独立地是直链，支链，取代或未取代的; R3是前药部分。 作为实例，前药可以具有如说明书中所示的任何式I-V的结构。